JP2007517900A5 - - Google Patents

Download PDF

Info

Publication number
JP2007517900A5
JP2007517900A5 JP2006549524A JP2006549524A JP2007517900A5 JP 2007517900 A5 JP2007517900 A5 JP 2007517900A5 JP 2006549524 A JP2006549524 A JP 2006549524A JP 2006549524 A JP2006549524 A JP 2006549524A JP 2007517900 A5 JP2007517900 A5 JP 2007517900A5
Authority
JP
Japan
Prior art keywords
substituted
alkyl
compound
aryl
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006549524A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007517900A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/000815 external-priority patent/WO2005070901A2/en
Publication of JP2007517900A publication Critical patent/JP2007517900A/ja
Publication of JP2007517900A5 publication Critical patent/JP2007517900A5/ja
Pending legal-status Critical Current

Links

JP2006549524A 2004-01-12 2005-01-11 ピリミジンホスホネート抗ウイルス化合物および使用方法 Pending JP2007517900A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53601004P 2004-01-12 2004-01-12
PCT/US2005/000815 WO2005070901A2 (en) 2004-01-12 2005-01-11 Pyrimidyl phosphonate antiviral compounds and methods of use

Publications (2)

Publication Number Publication Date
JP2007517900A JP2007517900A (ja) 2007-07-05
JP2007517900A5 true JP2007517900A5 (cg-RX-API-DMAC7.html) 2008-02-07

Family

ID=34806976

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006549524A Pending JP2007517900A (ja) 2004-01-12 2005-01-11 ピリミジンホスホネート抗ウイルス化合物および使用方法

Country Status (10)

Country Link
US (1) US20050282839A1 (cg-RX-API-DMAC7.html)
EP (1) EP1711476A2 (cg-RX-API-DMAC7.html)
JP (1) JP2007517900A (cg-RX-API-DMAC7.html)
KR (1) KR20060124701A (cg-RX-API-DMAC7.html)
CN (1) CN1934093A (cg-RX-API-DMAC7.html)
AU (1) AU2005206511A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0506786A (cg-RX-API-DMAC7.html)
CA (1) CA2552584A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA06007906A (cg-RX-API-DMAC7.html)
WO (1) WO2005070901A2 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004062613A2 (en) 2003-01-13 2004-07-29 Bristol-Myers Squibb Company Hiv integrase inhibitors
US7273859B2 (en) 2004-05-12 2007-09-25 Bristol-Myers Squibb Company HIV integrase inhibitors: cyclic pyrimidinone compounds
US7115601B2 (en) 2004-05-18 2006-10-03 Bristol-Myers Squibb Company HIV integrase inhibitors
AU2006272521A1 (en) * 2005-07-27 2007-02-01 Gilead Sciences, Inc. Antiviral phosphonate conjugates for inhibition of HIV
US20070129379A1 (en) * 2005-12-01 2007-06-07 Bristol-Myers Squibb Company Hiv integrase inhibitors
US7763630B2 (en) 2007-06-06 2010-07-27 Bristol-Myers Squibb Company HIV integrase inhibitors
US8143244B2 (en) 2009-02-26 2012-03-27 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US8975389B2 (en) 2009-03-02 2015-03-10 Alnylam Pharmaceuticals, Inc. Nucleic acid chemical modifications
US8383639B2 (en) 2009-10-15 2013-02-26 Bristol-Myers Squibb Company HIV integrase inhibitors
WO2011123621A2 (en) 2010-04-01 2011-10-06 Alnylam Pharmaceuticals Inc. 2' and 5' modified monomers and oligonucleotides
US9089574B2 (en) 2011-11-30 2015-07-28 Emory University Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
HK1211289A1 (en) * 2012-08-06 2016-05-20 Savira Pharmaceuticals Gmbh Dihydroxypyrimidine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
SI3125894T1 (sl) 2014-04-01 2020-12-31 Merck Sharp & Dohme Corp. Predzdravila inhibitorjev reverzne transkriptaze HIV
WO2016106050A1 (en) 2014-12-26 2016-06-30 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
RU2020116571A (ru) 2017-12-07 2021-11-22 Эмори Юниверсити N4-гидроксицитидин и производные и связанные с этим противовирусные применения

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816570A (en) * 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) * 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
DK0481214T3 (da) * 1990-09-14 1999-02-22 Acad Of Science Czech Republic Prolægemidler af phosphonater
US5798340A (en) * 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
US6312662B1 (en) * 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
WO2000036132A1 (en) * 1998-12-14 2000-06-22 Merck & Co., Inc. Hiv integrase inhibitors
US6245806B1 (en) * 1999-08-03 2001-06-12 Merck & Co., Inc. HIV integrase inhibitors
AU8009900A (en) * 1999-10-13 2001-04-23 Merck & Co., Inc. Hiv integrase inhibitors
CA2463975A1 (en) * 2001-10-26 2003-05-01 Maria Emilia Di Francesco Dihydroxypyrimidine carboxamide inhibitors of hiv integrase
DE122009000048I1 (de) * 2001-10-26 2010-04-08 Angeletti P Ist Richerche Bio N-substituierte hydroxypyrimidinoncarboxamid-hemmer der hiv-integrase
TW200408645A (en) * 2002-04-26 2004-06-01 Gilead Sciences Inc Non nucleoside reverse transcriptase inhibitors
WO2004062613A2 (en) * 2003-01-13 2004-07-29 Bristol-Myers Squibb Company Hiv integrase inhibitors
US7037908B2 (en) * 2003-04-24 2006-05-02 Bristol-Myers Squibb Company HIV integrase inhibitors
TW200526635A (en) * 2003-12-22 2005-08-16 Shionogi & Co Hydroxypyrimidinone derivative having HIV integrase inhibitory activity

Similar Documents

Publication Publication Date Title
US6150378A (en) Peptidyl-containing α-ketoamide cysteine and serine protease inhibitors
RU2003101969A (ru) Новые соединения, обладающие антибактериальной, противогрибковой и противоопухолевой активностью
JP2007532665A5 (cg-RX-API-DMAC7.html)
RU2005106846A (ru) Производные бензотиазола, характеризующиеся агонистической активностью к бета-2-адренорецепторам
RU2005105592A (ru) Макролидные соединения, обладающие противовоспалительной активностью
RU2006134005A (ru) Новые соединения, действующие как ингибиторы сериновой протеазы ns3 вируса гепатита с
GB2091724A (en) Sulpho-oxoazetidines
JP2005515255A5 (cg-RX-API-DMAC7.html)
RU2004109812A (ru) Ингибиторы цистеинпротеазы 2-циано-4-аминопиримидинового строения с ингибирующим действием на катепсин к для лечения воспалительных и других заболеваний
JP2009535307A5 (cg-RX-API-DMAC7.html)
CA2481261A1 (en) Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds
RU2006134003A (ru) Серосодержащие соединения, действующие как ингибиторы сериновой протеазы ns3 вируса гепатита с
AU749099B2 (en) Quinoline-containing alpha-ketoamide cysteine and serine protease inhibitors
DK1615613T3 (da) Quinoxalinyl-makrocykliske hepatitis C serin protease-inhibitorer
JP2006528621A5 (cg-RX-API-DMAC7.html)
FR2810979B1 (fr) Nouveaux derives de diphenyluree, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
TNSN04188A1 (fr) NOUVEAUX DERIVES D'INDOLIZINE 1,2,3 SUBSTITUEE, INHIBITEURS DES FGFs, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
RU2005116248A (ru) 9а-азалиды с противовоспалительной активностью
US20130121986A1 (en) Nitrogenated derivatives of pancratistatin
NZ331801A (en) Therapeutic agent for diabetes
ATE276257T1 (de) Pyrazinonderivate
JP2005511535A5 (cg-RX-API-DMAC7.html)
EP2321323A1 (fr) Derives dimeriques d'artemisinine et application en therapie anticancereuse
WO2004066952A3 (en) Benzoxazole, benzothiazole, and benzimidazole derivatives for the treatment of cancer and other diseases
WO2004075858A3 (en) Flavone acetic acid analogs and methods of use thereof